Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Acquisitions & Divestments: 2016-2024

Historic Change in Acquisitions & Divestments for Tg Therapeutics (TGTX) over the last 5 years, with Dec 2024 value amounting to $310.9 million.

  • Tg Therapeutics' Change in Acquisitions & Divestments fell 15.76% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.2 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $310.9 million for FY2024, which is 223.08% up from last year.
  • As of FY2024, Tg Therapeutics' Change in Acquisitions & Divestments stood at $310.9 million, which was up 223.08% from $96.2 million recorded in FY2023.
  • Tg Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $310.9 million during FY2024, with a 5-year trough of $55.6 million in FY2021.
  • Its 3-year average for Change in Acquisitions & Divestments is $164.8 million, with a median of $96.2 million in 2023.
  • Data for Tg Therapeutics' Change in Acquisitions & Divestments shows a peak YoY surged of 223.08% (in 2024) over the last 5 years.
  • Tg Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $55.6 million in 2021, then skyrocketed by 56.97% to $87.3 million in 2022, then grew by 10.26% to $96.2 million in 2023, then spiked by 223.08% to $310.9 million in 2024.